• Anixa Biosciences will present Phase 1 ovarian cancer CAR-T trial findings on December 14, 2026, at ESMO’s immuno-oncology congress in London.
• The Moffitt Cancer Center study of lira-cel has shown no dose-limiting toxicities, with preliminary observations including stable disease and prolonged survival.
• Treatment of the fifth patient cohort is complete; a sixth cohort receiving a higher dose is planned pending safety verification.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611040835PR_NEWS_USPR_____LA88483) on November 04, 2026, and is solely responsible for the information contained therein.